Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
Conditions
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
Trial Timeline
May 8, 2023 → Oct 1, 2024
NCT ID
NCT05947201About Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil is a phase 2 stage product being developed by Akeso for The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC. The current trial status is unknown. This product is registered under clinical trial identifier NCT05947201. Target conditions include The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05947201 | Phase 2 | UNKNOWN |
Competing Products
5 competing products in The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline | Johnson & Johnson | Pre-clinical | 23 |
| Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Letrozole | Novartis | Approved | 85 |
| Denosumab | Amgen | Phase 3 | 76 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |